NCCN announces the launch of the NCCN Guidelines – China Editions for Colon, Kidney, Non-Small Cell Lung, and Ovarian Cancers, which have been translated into Chinese and reflect regional adaptations. These Guidelines are now available on NCCNChina.org.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) announces the launch of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – China Editions for Colon, Kidney, Non-Small Cell Lung, and Ovarian Cancers, which have been translated into Chinese and are now available on NCCNChina.org. Based on the NCCN Guidelines™, the China Editions comprise the extensive expertise of more than 100 Chinese cancer specialists in collaboration with NCCN panel experts. The China Editions contain recommendations revised to account for genetic, pharmacological, and regulatory considerations of the Chinese population.
These latest China Editions add to an already extensive list of Chinese translations of the NCCN Guidelines, including those for Breast, Cervical, Gastric, Head & Neck, Pancreatic, and Rectal Cancers, Adult Cancer Pain, and Non-Hodgkin's Lymphomas, all of which are also available on NCCNChina.org.
The NCCN Guidelines are the recognized standard for clinical policy in oncology in the United States. Expert clinicians across Asia recognize and apply the NCCN Guidelines in practice and have collaborated with NCCN on the translation, adaptation, and implementation of national versions of the NCCN Guidelines. NCCN and cancer-care thought leaders in China have had a long-standing collaboration in the development of the NCCN Guidelines – China Editions - the most authoritative reference for oncology practice in China. Indeed, of the 1.1 million unique visitors to the NCCN website (NCCN.org) every year, almost 300,000 are from Asian countries. Forty-six thousand unique visitors are from China.
NCCN regularly collaborates with international organizations around the world to create and distribute translations of the NCCN Guidelines, which may include modifications representative of metabolic differences in populations, technological considerations, and regulatory status of agents used in cancer management, such as availabilities of drugs, biologics, devices, and procedures.
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.